Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) dropped 3.6% during mid-day trading on Tuesday . The company traded as low as $21.60 and last traded at $21.98, with a volume of 80,689 shares traded. The stock had previously closed at $22.80.

ATRA has been the subject of a number of recent research reports. Jefferies Group reissued a “buy” rating and issued a $22.00 target price (down from $26.00) on shares of Atara Biotherapeutics in a research report on Monday, May 9th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 19th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Citigroup Inc. raised their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research report on Friday, August 19th. Finally, JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $27.29.

The company’s market capitalization is $580.25 million. The company has a 50-day moving average price of $22.66 and a 200-day moving average price of $19.48.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts anticipate that Atara Biotherapeutics Inc. will post ($2.78) EPS for the current fiscal year.

In related news, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $22.32, for a total value of $30,042.72. Following the transaction, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $22.33, for a total value of $214,368.00. Following the completion of the transaction, the chief executive officer now directly owns 229,136 shares in the company, valued at $5,116,606.88. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Atara Biotherapeutics stock. Schwab Charles Investment Management Inc. raised its stake in shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 3.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 52,121 shares of the company’s stock after buying an additional 1,608 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.18% of Atara Biotherapeutics worth $1,377,000 as of its most recent filing with the SEC.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.